WF60.F MindBio Therapeutics Corp.
- Market cap
- EUR 615K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Mar 2026.
Is WF60.F undervalued?
Graham numberThe Graham number of MindBio Therapeutics Corp. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MindBio Therapeutics Corp. fundamental analysis
No fundamental analysis for MindBio Therapeutics Corp. yet.
MindBio Therapeutics Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MindBio Therapeutics Corp.
MindBio Therapeutics Corp., together with its subsidiaries, research, develops, and tests psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically proven treatments for debilitating health conditions, such as de…
Full company profileMindBio Therapeutics Corp. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MindBio Therapeutics Corp. annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -5.58M | -3.16M | -56.0K | -1.93M | -7.58M |
| EBITDA | -7.25M | -3.84M | -56.6K | -2.23M | -7.58M |
| Net Income | -7.47M | -4.29M | -411K | -2.81M | -7.58M |
| EPS | -0.06 | -0.03 | 0.00 | -1.98 | -1.04 |
| Balance Sheet | |||||
| Total Assets | 1.61M | 673K | 194K | 116K | 1.19M |
| Total Liabilities | 5.84M | 6.09M | 5.60M | 2.56M | 2.52M |
| Shareholders' Equity | -4.23M | -5.36M | -5.35M | -2.38M | -1.27M |
| Cash & Short-term Investments | 1.31M | 319K | 139K | 64.0K | 67.6K |
| Cash Flow | |||||
| Operating Cash Flow | -4.72M | -2.21M | -383K | -494K | -1.90M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -4.72M | -2.21M | -383K | -494K | -1.90M |
| Ratios | |||||
| ROA | -462.9% | -637.0% | -211.7% | -2,411.5% | -636.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
MindBio Therapeutics Corp. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | AUD 787K | 0.01 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:400 on Nov 6, 2025.
Who owns MindBio Therapeutics Corp.
- Insiders 3.82%
- Institutions 0.00%
- Public & others 96.18%
- Shares outstanding 9.68M
- Free float 7.13M
MindBio Therapeutics Corp. company profile
- Company name
- MindBio Therapeutics Corp.
- Ticker
- WF60.F
- ISIN
- CA60256C2076
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 1055 West Georgia Street, Vancouver, BC, Canada, V6E 4N7
- Website
- mindbiotherapeutics.com
About MindBio Therapeutics Corp.
MindBio Therapeutics Corp., together with its subsidiaries, research, develops, and tests psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically proven treatments for debilitating health conditions, such as depression, anxiety, PTSD, and chronic pain. MindBio Therapeutics Corp. was incorporated in 2021 and is headquartered in Vancouver, Canada.
MindBio Therapeutics Corp. management
2- Mr. Justin Adam HankaCo Founder, CEO & Director · born 1974
- Mr. John M. DinanChief Financial Officer · born 1958